3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
10
Breast
3
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
10
Carcinoma, Renal Cell
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
abemaciclib
×
Genitourinary
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled